Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis

Table 1 Effect size of each treatment versus Placebo (MD (95% Crl) for MHDS, MMDs, MSQ, and HIT-6, and RRs (95% Crl) for ≥ 50% MHDs and MMDs)

GRADE rating and interpretation
High: Definitely more beneficial than Placebo
Moderate: Probably more beneficial than Placebo; Probably less beneficial than Placebo
Low: May be more beneficial than Placebo
Abbreviations: MHDs Monthly Headache Days, MMDs Monthly Migraine Days, MSQ-RR Migraine-Specific QoL-Restrictive Role, MSQ-PR Migraine-Specific QoL-Preventative Role, MSQ-EF Migraine-Specific QoL-Emotional Function, HIT-6 Headache Impact Test-6, ≥ 50% MHDs 50% or more response in MHDs reported in four trials (n= 3,039) [34, 41, 45, 46], ≥ 50% MMDs 50% or more response in MMDs reported in seven trials (n = 4,695) [32, 38,39,40, 43,44,45,46,47,48,49,50]
^adowngraded due to risk of bias
^bdowngraded due to imprecision

ISSN: 1129-2377